Document Detail

Protease inhibitor monotherapy as maintenance regimen in patients with HIV infection.
MedLine Citation:
PMID:  23016538     Owner:  NLM     Status:  MEDLINE    
Despite the remarkable success of combination antiretroviral therapy, usually including the association of three antiretroviral drugs selected from two different classes, the possibility of treating HIV-infected patients with one single potent agent as simplified maintenance regimen has attracted clinicians and researchers over the past years. Monotherapy with one ritonavir-boosted protease inhibitor in subjects with persistently suppressed plasma HIV RNA offers several potential advantages, such as avoiding the long-term toxicity associated with nucleoside/nucleotide analog, reducing costs, preventing drug-drug interactions, and preserving future treatment options. Several controlled and uncontrolled studies have assessed efficacy and safety of this monotherapy strategy, and the majority of available data concern lopinavir/ritonavir and darunavir/ritonavir. The virological efficacy of these boosted protease inhibitors as monotherapy is slightly lower than that of standard therapy, but the risk of resistance development is minimal and the re-introduction of nucleoside analogues usually leads to a re-suppression of the plasma viral load. Even though currently there is no consensus about the clinical use of protease inhibitor monotherapy for the treatment of HIV infection, this strategy seems an option for selected patients on stable combination therapy, with persistently suppressed plasma viral load, and without a history of virologic failure while receiving protease inhibitors. The aim of this article is to review and summarize the most recent randomized and observational studies which have evaluated efficacy and safety of the protease inhibitor monotherapy.
Leonardo Calza; Roberto Manfredi
Related Documents :
23274788 - Spray drying tenofovir loaded mucoadhesive and ph-sensitive microspheres intended for h...
23291408 - Phylogenetic and demographic characterization of hiv-1 transmission in madrid, spain.
24461198 - Systematic review with meta-analysis: do interferon lambda 3 polymorphisms predict the ...
24844548 - An echocardiographic study of infective endocarditis, with special reference to patient...
16611438 - Cotrimoxazole prophylaxis for hiv-positive tb patients in developing countries.
22031628 - Circumscribed lenticular anetoderma in an hiv-infected man with a history of syphilis a...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Current HIV research     Volume:  10     ISSN:  1873-4251     ISO Abbreviation:  Curr. HIV Res.     Publication Date:  2012 Dec 
Date Detail:
Created Date:  2013-01-01     Completed Date:  2013-05-15     Revised Date:  2013-06-03    
Medline Journal Info:
Nlm Unique ID:  101156990     Medline TA:  Curr HIV Res     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  661-72     Citation Subset:  IM    
Department of Internal Medicine, Geriatrics and Nephrologic Diseases, Section of Infectious Diseases, S. Orsola-Malpighi, "Alma Mater Studiorum" University of Bologna, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
HIV Infections / drug therapy*,  virology
HIV Protease Inhibitors / therapeutic use*
Lopinavir / therapeutic use
Maintenance Chemotherapy / methods*
RNA, Viral / drug effects
Randomized Controlled Trials as Topic
Ritonavir / therapeutic use
Sulfonamides / therapeutic use
Viral Load
Reg. No./Substance:
0/HIV Protease Inhibitors; 0/Lopinavir; 0/RNA, Viral; 0/Ritonavir; 0/Sulfonamides; YO603Y8113/darunavir

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Felt obligation and the family life cycle: A study on intergenerational relationships.
Next Document:  Is social capital as perceived by the medical director associated with coordination among hospital s...